<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00700544</url>
  </required_header>
  <id_info>
    <org_study_id>LAM SA 2002</org_study_id>
    <nct_id>NCT00700544</nct_id>
  </id_info>
  <brief_title>Treatment Outcome in Elderly Patients</brief_title>
  <official_title>Adjonction of Androgenotheapy for Post-Remission Treatment of Elderly Patients With Acute Myeloid Leukemia - Results of the Multicenter Goelams SA-2002 Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BGMT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter randomized trial evaluating the possible benefit of androgens during post&#xD;
      remission therapy in an attempt to improve the outcome of AML in older patients.All patients&#xD;
      received the ICL regimen as induction and were randomized to receive, after achieving CR or&#xD;
      PR, a maintenance therapy including or not androgens. Patients randomized with androgens&#xD;
      additionally received 10 to 20 mg according to body weigh of norethandrolone daily for up to&#xD;
      2 years&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Induction Therapy:&#xD;
&#xD;
             -  Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1&#xD;
&#xD;
             -  if CR or PR: randomisation = maintenance therapy including or not androgens&#xD;
&#xD;
        -  Maintenance therapy :&#xD;
&#xD;
             -  6 courses of reinduction with idarubicin (8mg/m2 d1) and cytarabine (100mg/m2d1-5,&#xD;
                subcutaneously) every 3 months, and, between these courses, a continuous regimen of&#xD;
                methotrexate and 6-mercaptopurine.&#xD;
&#xD;
             -  Patients randomized with androgens additionally received 10 to 20 mg according to&#xD;
                body weigh of norethandrolone daily for up to 2 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study was to assess the ability of androgens to increase DFS.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objective was to improved EFS and OS and to assess side effects and toxicity of androgenotherapy</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>AML</condition>
  <condition>Elderly Patients</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR&#xD;
maintenance therapy every 3 months = 6 courses of reinduction with :&#xD;
-idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5 ), subcutaneously&#xD;
between the courses, a continuous regimen of methotrexate and 6-mercaptopurine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR&#xD;
maintenance therapy every 3 months = 6 courses of reinduction with :&#xD;
idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5, subcutaneously)&#xD;
10 to 20 mg (according to body weigh) of norethandrolone daily&#xD;
between the courses, a continuous regimen of methotrexate and 6-mercaptopurine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy treatment (see arm) + norethandrolone</intervention_name>
    <description>oral form&#xD;
Dosage:&#xD;
10 mg in patients with a weight &lt; 60 kgs 20 mg in patients with a weight &gt; 60 kgs frequency: every day Duration: 2 years</description>
    <arm_group_label>A</arm_group_label>
    <other_name>norethandrolone = nilevar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy treatment (see arms)</intervention_name>
    <description>Induction chemotherapy + maintenance chemotherapy</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Induction chemotherapy + maintenance chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 60 years or more&#xD;
&#xD;
          -  &quot;de novo&quot; AML according to FAB criteria&#xD;
&#xD;
          -  AML with 20% or more myeloid marrow blasts&#xD;
&#xD;
          -  signed and dated informed consent&#xD;
&#xD;
          -  OMS score &lt; 3&#xD;
&#xD;
          -  Life expectancy &gt; 1 month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients aged &lt; 60 years&#xD;
&#xD;
          -  or AML M3&#xD;
&#xD;
          -  or not classificated according to FAB criteria&#xD;
&#xD;
          -  or extramedular localisation of AML&#xD;
&#xD;
          -  OMS score ≥ 3&#xD;
&#xD;
          -  clinical Abnormal Cardiac fonction or with left ejection fraction &lt; 40 %&#xD;
&#xD;
          -  abnormal renal function with creatinine clearance &lt; 50/ml/mn/m²&#xD;
&#xD;
          -  abnormal hepatic function&#xD;
&#xD;
          -  previous cerebral stroke&#xD;
&#xD;
          -  previous malignancy : prostate, breast cancer (males)&#xD;
&#xD;
          -  PSA dosage &gt; 4&#xD;
&#xD;
          -  Any coexisting medical or psychological condition that would pleclude participation in&#xD;
             the required study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean jacques SOTTO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GOELAMS/BGMT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnaud PIGNEUX, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>GOELAMS/BGMT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francis WITZ, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arnaud PIGNEUX</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <last_update_submitted>June 13, 2008</last_update_submitted>
  <last_update_submitted_qc>June 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>CHU Grenoble Pr Jean Jacques SOTTO</name_title>
    <organization>GOELAMS BGMT</organization>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>elderly patients</keyword>
  <keyword>Treatment outcome</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norethandrolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

